132 related articles for article (PubMed ID: 36603431)
1. CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis.
Wu J; Zhou Z; Li J; Liu H; Zhang H; Zhang J; Huang W; He Y; Zhu S; Huo M; Liu M; Zhang C
Drug Resist Updat; 2023 Jan; 66():100913. PubMed ID: 36603431
[TBL] [Abstract][Full Text] [Related]
2. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
Nio K; Yamashita T; Okada H; Kondo M; Hayashi T; Hara Y; Nomura Y; Zeng SS; Yoshida M; Hayashi T; Sunagozaka H; Oishi N; Honda M; Kaneko S
J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183
[TBL] [Abstract][Full Text] [Related]
3. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
4. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
Hou MF; Luo CW; Chang TM; Hung WC; Chen TY; Tsai YL; Chai CY; Pan MR
Exp Cell Res; 2017 Oct; 359(2):458-465. PubMed ID: 28842166
[TBL] [Abstract][Full Text] [Related]
5. CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
Xu N; Liu F; Wu S; Ye M; Ge H; Zhang M; Song Y; Tong L; Zhou J; Bai C
BMC Cancer; 2020 Mar; 20(1):262. PubMed ID: 32228507
[TBL] [Abstract][Full Text] [Related]
6. RNAi screens identify CHD4 as an essential gene in breast cancer growth.
D'Alesio C; Punzi S; Cicalese A; Fornasari L; Furia L; Riva L; Carugo A; Curigliano G; Criscitiello C; Pruneri G; Pelicci PG; Faretta M; Bossi D; Lanfrancone L
Oncotarget; 2016 Dec; 7(49):80901-80915. PubMed ID: 27779108
[TBL] [Abstract][Full Text] [Related]
7. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
8. Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer.
Li L; Cui Y; Ye L; Zhao Z; Jiang WG; Ji J
Int J Oncol; 2018 Sep; 53(3):1171-1182. PubMed ID: 29956751
[TBL] [Abstract][Full Text] [Related]
9. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
[TBL] [Abstract][Full Text] [Related]
10. The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.
Zhang JX; Xu Y; Gao Y; Chen C; Zheng ZS; Yun M; Weng HW; Xie D; Ye S
Mol Cancer; 2017 Jan; 16(1):18. PubMed ID: 28114937
[TBL] [Abstract][Full Text] [Related]
12. CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer.
Chang CL; Huang CR; Chang SJ; Wu CC; Chen HH; Luo CW; Yip HK
Int J Biol Sci; 2021; 17(7):1660-1670. PubMed ID: 33994851
[TBL] [Abstract][Full Text] [Related]
13. CHD4 Predicts Aggressiveness in PTC Patients and Promotes Cancer Stemness and EMT in PTC Cells.
Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Alobaisi K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419089
[TBL] [Abstract][Full Text] [Related]
14. Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis.
Zu LD; Peng XC; Zeng Z; Wang JL; Meng LL; Shen WW; Hu CT; Yang Y; Fu GH
J Exp Clin Cancer Res; 2018 Jun; 37(1):115. PubMed ID: 29866191
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Wu QN; Liao YF; Lu YX; Wang Y; Lu JH; Zeng ZL; Huang QT; Sheng H; Yun JP; Xie D; Ju HQ; Xu RH
Cancer Lett; 2018 Jan; 412():243-255. PubMed ID: 29050982
[TBL] [Abstract][Full Text] [Related]
16. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
[TBL] [Abstract][Full Text] [Related]
17. Ginkgo biloba extract enhances chemotherapy sensitivity and reverses chemoresistance through suppression of the KSR1-mediated ERK1/2 pathway in gastric cancer cells.
Liu SQ; Xu CY; Qin MB; Tan L; Zhuge CF; Mao YB; Lai MY; Huang JA
Oncol Rep; 2015 Jun; 33(6):2871-82. PubMed ID: 25962735
[TBL] [Abstract][Full Text] [Related]
18. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
[TBL] [Abstract][Full Text] [Related]
19. Acetyltransferase p300 collaborates with chromodomain helicase DNA-binding protein 4 (CHD4) to facilitate DNA double-strand break repair.
Qi W; Chen H; Xiao T; Wang R; Li T; Han L; Zeng X
Mutagenesis; 2016 Mar; 31(2):193-203. PubMed ID: 26546801
[TBL] [Abstract][Full Text] [Related]
20. CHD4 Promotes Breast Cancer Progression as a Coactivator of Hypoxia-Inducible Factors.
Wang Y; Chen Y; Bao L; Zhang B; Wang JE; Kumar A; Xing C; Wang Y; Luo W
Cancer Res; 2020 Sep; 80(18):3880-3891. PubMed ID: 32699137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
